A New Radiopharmaceutical 225 Ac-DOTA-IBA in the Treatment of a Case of Bone Metastases.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 37167345.
- Also identified by DOI 10.1097/RLU.0000000000004688.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
α-Emitter 225 Ac has been considered a candidate for targeted α-therapy. DOTA-IBA is new a precursor targeting bone metastasis. It can be used for radionuclide labeling with 225 Ac. We present a case with refractory bone pain for bone metastasis, who demonstrated an excellent therapy response after 1 cycle of 225 Ac-DOTA-IBA therapy. Moreover, the patient did not have any observable adverse effects.
Medical subject headings
- Radiopharmaceuticals
- Bone Neoplasms